ESG Data

アンカーリンク用

Sustainability data is included. Historical data are included in the annual Sustainability Report.
To ensure the reliability of the reported figures, we have received third-party assurance for some of the environmental and social data  in the “SUSTAINABILITY DATA 2024 (PDF version)”. In the “SUSTAINABILITY DATA 2024 (PDF version),” data for FY 2023 that has received assurance is marked with.

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

  • Sites where data were collected:
    [Non-consolidated] Fujiyama Plant, Yamaguchi Plant (Added from 2018), Joto Pharmaceutical Product Development Center, Minase Research Institute, Tsukuba Research Institute, Fomer Fukui Research Institute, Head Office, sales offices and other offices, etc. (logistics centers have been added from FY2021 only for waste data)
    [Group companies] ONO PHARMA USA, INC., ONO PHARMA UK LTD, ONO PHARMA KOREA CO., LTD, ONO PHARMA TAIWAN CO., LTD., and Ono Pharma UD Co., Ltd.
     Due to rounding of the figures in the table, the breakdown totals may not always equal the overall totals (Same as environmental data below)
Scope1+2 GHG emissions (Unit:kt-CO2)
Item Scope FY2017
(Base year)
FY2021 FY2022 FY2023
Scope 1 (by GHG type) Energy-derived Non-consolidated 8.5 9.8 8.0 6.6
Group Companies - - 0.0 0.0
Non-energy-derived (HFCs, HCFCs) Non-consolidated 0.2 0.0 0.2 0.1
Group Companies - - 0.0 0.0
Total - - 8.2 6.7
Scope 2 Non-consolidated 21.1 13.7 10.2 9.4
Group Companies - - 0.1 0.2
Total - - 10.4 9.5
Scope 1+2 (Total) (a) Non-consolidated 29.8 23.6 18.4 16.0
Group Companies - - 0.1 0.2
Total - - 18.6 16.2
Amount of CO2 offset due to voluntary credit(Carbon-neutral city gas purchased) (b) Non-consolidated - 0.6 0.7 1.7
GHG emissions after offset (a-b) Subtotal
(Non-consolidated)
- 23.0 17.7 14.4
Total - - 17.9 14.5
  • GHG emissions are calculated using the following formula. These are market-based data.
    [Domestic bases] Calculated in accordance with the Act on Promotion of Global Warming Countermeasures
    [Overseas bases] Calculated by multiplying the amount of electricity purchased by overseas bases by the emission factor published by the electric power company or the country-specific emission factor published by the IEA.
Scope3 GHG emissions (Unit:kt-CO2)
CategoryCalculation method / notes Scope FY2017
(Base year)
FY2021 FY2022 FY2023
01 Purchased goods and services Calculated by multiplying the Scope 1+2 GHG emissions of our major suppliers of raw materials (covering more than 80% of the purchase price of raw materials) by our transaction volume as a percentage of the sales volume of the suppliers. For suppliers of raw materials other than those mentioned above, the calculation is based on the ratio of GHG emissions to the transaction value of major suppliers. Non-consolidated 8.5 13.8 4.8 -
02 Capital goods Calculated by multiplying the price of capital goods treated as fixed assets (investment in the expansion and maintenance of facilities), excluding land, by the emission factor. Consolidated 52.6 26.4 21.3 18.4
03 Fuel- and energy-related activities not included in scope 1 or scope 2 Calculated by multiplying the amount of purchased electricity (excluding renewable energy) by the emission factor. Non-consolidated 1.5 3.0* 2.8* 2.9
04 Upstream transportation and distribution Calculated by multiplying the emission factor by the transportation data from our own production sites and distribution centers to the delivery destination 0.1 0.1 0.1 0.2
05 Waste generated in operations Calculated by multiplying the weight value of waste by an emission factor for each type of waste. 0.3 0.3 0.3 0.3
06 Business travel Calculated by multiplying the amount of transportation expenses paid by airplanes and Shinkansen by the emission factor. 2.5 0.5 1.3 3.1
07 Employee commuting ・Calculated by multiplying the amount paid for commuting transportation by the emission coefficient.
・Including commuting by car from FY2021
0.4 0.7 0.7 0.7
08 Upstream leased assets Calculated by multiplying the fuel consumption of leased cars by the emission factor 3.5 2.1 1.9 1.9
09 Downstream transportation and distribution Calculated by multiplying the Scope 1+2 GHG emissions of our major pharmaceutical wholesalers by the value of our transactions as a percentage of the sales volume of our major pharmaceutical wholesalers. 5.3 5.5 7.5 -
10 Processing of sold products Not relevant - - - -
11 Use of sold products Not relevant - - - -
12 End-of-life treatment of sold products Calculated by multiplying the weight of sold product containers and packaging by the emission factor. 0.1 0.1 0.2 0.2
13 Downstream leased assets Calculated by multiplying the floor area of the building in question by the emission factor for each use. 0.3 0.3 0.3 0.3
14 Franchises Not relevant - - - -
15 Investments Not relevant - - - -
Total   75.1 52.8 41.1 -
  • The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2017, Ver. 2.4;, FY2021, Ver. 3.2; FY2022, Ver. 3.3, FY2023, Ver. 3.4)," published by the Ministry of the Environment, Government of Japan.
    Categories 1 and 9 and their total for FY2023 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.
  • For Category 3, data from previous years (FY2021 and FY2022) has been revised due to more sophisticated calculation methods.
Energy consumption (Unit:MWh)
Item Scope FY2017
(Base year)
FY2021 FY2022 FY2023
Energy consumption Non-consolidated 89,163.1 99,499.9 86,067.6 82,285.0
Group Companies - - 344.1 381.1
Total - - 86,411.7 82,666.1
Total electricity consumption and Renewable energy usage rate
Item Scope Unit FY2017
(Base year)
FY2021 FY2022 FY2023
Electricity consumption Private power generation (renewable) (solar power generation) Non-consolidated MWh 55.3 61.9 64.4 64.0
Group Companies - - 0.0 0.0
Purchased electricity (renewable) Non-consolidated - 2,040.0 3,480.0 20,281.2
Group Companies - - 0.0 0.0
Private power generation (non-renewable) Non-consolidated 7,927.0 8,283.7 7,285.0 5,596.7
Group Companies - - 0.0 0.0
Purchased electricity (non-renewable) Non-consolidated 41,820.1 42,833.5 37,821.6 21,543.7
Group Companies - - 343.7 380.7
Subtotal (Non-consolidated total electricity consumption) 49,802.4 53,219.2 48,651.0 47,485.5
Total (total electricity consumption) - - 48,994.7 47,866.3
Certificates usage of renewable energy Solar power generation Non-consolidated MWh - 3,937.9 0.0 0.0
Biomass power generation - 3,000.0 6,907.0 0.0
Renewable energy usage* Total MWh 55.3 9,039.9 10,451.4 20,345.2
Renewable energy usage rate (renewable energy usage / total electricity consumption) Subtotal (Non-consolidated) % 0.1 17.0 21.5 42.8
Total - - 21.3 42.5
  • Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Certificates usage of renewable energy
Water intake and Discharged water volume by site (unit: 1,000 m3)
Site name River in the area Drainage destination FY2017
(Base year)
FY2021 FY2022 FY2023
Water intake volume Discharged water volume Water intake volume Discharged water volume Water intake volume Discharged water volume Water intake volume Discharged water volume
Fujiyama Plant Fuji River River 205.6 148.6 138.7 110.2 122.9 100.1 115.8 94.6*1
Yamaguchi Plant Fushino River River - - 21.6 20.0 22.8 20.9 24.4 22.9
Joto Pharmaceutical Product Development Center Yodo River Sewer 5.5 5.5 3.9 3.9 3.4 3.4
3.7 3.7
Minase Research Institute Yodo River Sewer 51.3 51.3 31.5 31.5 32.2 32.2 30.1 30.0
Tsukuba Research Institute Lake Kasumigaura Sewer 8.1 8.1 7.07.04.74.7 5.0 5.0
Fomer Fukui Research Institute Kuzuryu River Sewer 38.7 5.2 6.6 1.9 0.8 0.2 0.0
0.0
Head Office and other sites in Japan*2 Rivers/lake in the areas around each business site*3 Sewer 15.9
15.9 10.0 10.0 9.5 9.5 11.0 11.0
Total 325.1 234.6 219.4 184.5 196.4 171.2 189.9 167.1
  • The discharged water volume for the Fujiyama Plant in FY2023 has been corrected by the ratio of deviation (the average of the most recent three years) between the meters before and after wastewater treatment because an error was identified in the meter settings after wastewater treatment. 
  • Added Ono Pharmaceutical UD Co., Ltd. from FY2023
  • Major basins: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
Waste Management, and Recycling Containers and Product Packaging
Item Unit FY2021 FY2022 FY2023
Industrial waste Waste generated t 479.1 492.8 569.7
[Waste breakdown]
Special management industrial waste (hazardous waste)*
t 170.3 142.5 145.5
final landfill disposal t 0.2 0.1 0.1
final landfill disposal rate % 0.04 0.02 0.02
final landfill disposal (Non-industrial waste is included) t 5.3 4.4 3.3
Container and packaging usage Plastic t 147.0 173.4 193.5
Paper t 175.6 163.4 163.8
Glass (colorless) t 0.0 0.0 0.0
Glass (brown) t 0.2 0.2 0.2
Obligatory recycling amount Plastic t 36.6 52.2 56.2
Paper t 1.3 0.8 0.8
Glass (colorless) t 0.0 0.0 0.0
Glass (brown) t 0.0 0.0 0.0
Commissioning fee paid for recycling 1,000 yen 1,958 3,049 3,506
  • The data coverage is non-consolidated.
  • Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.
Prevention of Air Pollution and Water Pollution
Item Unit FY2021 FY2022 FY2023
Emissions into the air SOx t 0.0 0.0 0.0
NOx t 8.3 4.9 5.0
Particulate matter t 0.3 0.3 0.3
PRTR substance t 0.3 0.3 0.0*
Emissions into water Wastewater 1,000m3 174.5 171.2 167.1
BOD t 1.3 1.2 0.8
PRTR substance t 0.0 0.0 0.0*
  • The data coverage is non-consolidated.
  • Acetonitrile has been excluded from the PRTR substances since FY2023
Management of Chemicals (PRTR substances)
Item Unit FY2021 FY2022 FY2023
Amount handled by the notified facilities Acetonitrile t 9.3 6.9 -*
Normal-hexane t 2.3 1.8 1.7
Total t 11.6 8.7 1.7
Dioxins mg-TEQ - - -
Notified release (into the air) Acetonitrile t 0.3 0.3 -*
Normal-hexane t 0.0 0.0 0.0
Total t 0.3 0.3 0.0
Dioxins mg-TEQ - - -
Notified release (into public waters) Acetonitrile t 0.0 0.0 -*
Normal-hexane t 0.0 0.0 0.0
Total t 0.0 0.0 0.0
Dioxins mg-TEQ - - -
Notified transfer (contained in waste) Acetonitrile t 8.9 6.6 -*
Normal-hexane t 2.3 1.8 1.7
Total t 11.3 8.4 1.7
Dioxins mg-TEQ - - -
Notified transfer (Into public sewage) Acetonitrile t 0.0 0.0 -*
Normal-hexane t 0.0 0.0 0.0
Total t 0.0 0.0 0.0
Dioxins mg-TEQ - - -
Notified release and transfer (total) Acetonitrile t 9.3 6.9 -*
Normal-hexane t 2.3 1.8 1.7
Total t 11.6 8.7 1.7
Dioxins mg-TEQ - - -
  • The data coverage is non-consolidated.
  • Acetonitrile has been excluded from the PRTR substances since FY2023
Environmental Management
Item Unit FY2021 FY2022 FY2023
Acquisition rate of ISO 14001 certification for production sites % 100 100 100
  • The data coverage is non-consolidated.
Environmental Violations
Item Unit FY2021 FY2022 FY2023
Number of breaches of legal obligation/regulatory violations Cases 0 0 0
Amount of breach-/violation-related fines Million yen 0 0 0
Environmental liabilities as of fiscal year-end Million yen 0 0 0
  • The data coverage is non-consolidated.
    Breach/violation with a fine of US$10,000 or more are covered. The above includes violations related to air and soil pollution, noise, vibration, and water quality.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item Scope Unit FY2021 FY2022 FY2023
Composition of Board of Directors Directors (Total) Non-consolidated Persons 8 8 7
Outside Directors Non-consolidated Persons 3 3 3
Female Directors Non-consolidated Persons 1 1 1
Composition of Audit & Supervisory Board Audit & Supervisory Board Members (Total) Non-consolidated Persons 4 4 4
Outside Audit & Supervisory Board Members Non-consolidated Persons 2 2 2
Female Outside Audit & Supervisory Board Members Non-consolidated Persons 1 1 1
Number of the Meeting of the Board of Directors Non-consolidated Times 15 12 12
Number of the Meeting of the Audit & Supervisory Board Non-consolidated Times 16 15 15
Attendance rate at the Meeting of the Board of Directors Directors Non-consolidated % 100 100 94.0
Audit & Supervisory Board Members Non-consolidated % 100 97.9 100
Compliance
Item Scope Unit FY2021 FY2022 FY2023
Compliance training attendance rate Non-consolidated % 100 100 100
Number of reports Bribery cases Non-consolidated Incidents 0 0 0
Discrimination and harassment related Non-consolidated Incidents 29 22 25
Personnel and labor management related Non-consolidated Incidents 2 6 8
Customer privacy data related Non-consolidated Incidents - 0 0
Conflicts of interest related Non-consolidated Incidents - 0 0
Money laundering or Insider trading related Non-consolidated Incidents - 0 0
Others Non-consolidated Incidents 29 22 16
Total Non-consolidated Incidents 60 50 49
Number of compliance violations(Disciplinary action cases) Bribery cases Non-consolidated Incidents 0 0 0
Discrimination and harassment related Non-consolidated Incidents 0 4 5
Personnel and labor management related Non-consolidated Incidents 1 0 0
Customer privacy data related Non-consolidated Incidents - 0 0
Conflicts of interest related Non-consolidated Incidents - 0 0
Money laundering or Insider trading related Non-consolidated Incidents - 0 0
Others Non-consolidated Incidents 10 9 1
Total Non-consolidated Incidents 11 13 6
Costs for legal violations Non-consolidated Million yen 0 0 0
Number of facilitation payments Non-consolidated Incidents 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system